# Akebia Therapeutics, Inc. (AKBA) Stock Analysis: A 90% Upside Potential in the Healthcare Sector

- Link: https://www.directorstalkinterviews.com/akebia-therapeutics-inc-akba-stock-analysis-a-90-upside-potential-in-the-healthcare-sector/4121208045
- Published: 2025-07-18T10:30:18+01:00
- Author: Madison Wilson

Akebia Therapeutics, Inc. (NASDAQ: AKBA), a key player in the biopharmaceutical 
landscape, stands out with an impressive potential upside of 90.72% according to
current analyst ratings. Headquartered in Cambridge, Massachusetts, Akebia is focused
on developing and commercializing therapeutics aimed at addressing unmet needs in
the treatment of kidney diseases.

Currently trading at $3.88, Akebia’s stock has shown resilience, hovering near the
upper end of its 52-week range of $1.11 to $3.99. This reflects a notable recovery
and growth trajectory, particularly impressive in the volatile biotech sector. The
company’s market capitalization of $1.02 billion underscores its significant presence
in the healthcare industry, specifically within the drug manufacturing sector focusing
on specialty and generic products.

One of Akebia’s flagship products, Vafseo (vadadustat), is making significant headway
in the treatment of anemia due to chronic kidney disease (CKD), both for patients
who are dialysis-dependent and those who are not. In addition, Auryxia, another 
key product, serves a dual role in managing serum phosphorus levels and treating
iron deficiency anemia in different CKD patient groups. These innovations highlight
Akebia’s robust product pipeline and its potential impact on patient care.

The company’s recent revenue growth of 75.80% is a remarkable feat, indicating strong
operational performance and effective market strategies. However, the current Earnings
Per Share (EPS) of -0.21 and the absence of a trailing P/E ratio suggest that Akebia
is still navigating through the profitability phase typical of biopharmaceutical
firms investing heavily in research and development. Despite these challenges, Akebia
has managed to maintain a healthy free cash flow of approximately $12.96 million,
suggesting sound financial management.

From a valuation perspective, Akebia’s forward P/E ratio stands at 14.64, providing
a lens into potential future profitability as the company matures and further penetrates
the market with its therapeutic offerings. Analysts are optimistic, with five buy
ratings and no holds or sells, projecting a target price range of $6.00 to $10.00.
These targets reflect confidence in Akebia’s strategic direction and growth potential,
supported by its innovative product lineup and strategic partnerships, such as those
with Mitsubishi Tanabe Pharma Corporation.

Technically, Akebia’s 50-day moving average of $3.34 and 200-day moving average 
of $2.26 indicate a positive trend, suggesting upward momentum. However, a Relative
Strength Index (RSI) of 29.84 signals that the stock is currently in oversold territory,
which might present a buying opportunity for investors seeking entry points amid
market fluctuations.

While the company does not currently offer a dividend, its zero payout ratio aligns
with its growth-focused strategy, reinvesting earnings to fuel further research 
and development. This approach is typical of emerging biotech firms prioritizing
long-term value creation over short-term shareholder returns.

In summary, Akebia Therapeutics, Inc. presents a compelling investment opportunity
within the healthcare sector, driven by its innovative kidney disease treatments
and potential for significant market impact. With a strong growth narrative and 
favorable analyst ratings, Akebia is well-positioned for investors seeking exposure
to a promising biopharmaceutical stock with substantial upside potential.

Share on: